A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

I4X-MC-JFCU -

The purpose of this study is to evaluate the safety and efficacy of two new medicines, (Necitumumab and Abemaciclib), administered in combination in participants with advanced lung cancer (stage IV non-small-cell lung cancer).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Lung Cancer
What the trial is testing?
Necitumumab, Abemaciclib
Could I receive a Placebo?
No
Enrollment Goal
66
Trial Dates
Jun 4, 2015 - May 28, 2019
How long will I be in the trial?
You may continue participation in this study for as long as your study doctor determines that you are benefiting from the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.